Scpharmaceuticals ( (SCPH) ) has released its Q1 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
scPharmaceuticals Inc., a pharmaceutical company focused on advancing cardiorenal healthcare through innovative treatments, reported its financial results for the first quarter of 2025, highlighting significant growth and strategic developments.
The company generated $11.8 million in net revenue from its flagship product, FUROSCIX, marking a 93% increase compared to the same period last year. This growth was bolstered by the recent FDA approval and launch of FUROSCIX for treating edema in patients with chronic kidney disease (CKD), which has been well-received by nephrologists.
Key financial metrics showed a substantial increase in product revenues and costs, with $3.5 million in product revenue costs compared to $1.8 million in the previous year. Research and development expenses rose to $4.6 million, reflecting increased pharmaceutical development and employee costs. Despite these expenses, the company saw a notable rise in FUROSCIX prescriptions and sales to Integrated Delivery Networks, which grew by 119% from the previous quarter.
Looking ahead, scPharmaceuticals is preparing for the sNDA submission of its 80mg/1mL FUROSCIX Autoinjector in the third quarter of 2025, aiming to significantly reduce treatment time and enhance patient care. The company remains optimistic about continued growth and expansion efforts throughout the year.